Quantcast

Latest Perrigo Stories

2014-09-29 08:30:21

DUBLIN, Sept. 29, 2014 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO; TASE) announced today that it has transferred a portfolio of preclinical research assets, which it acquired through its December 2013 acquisition of Elan Corporation plc, to drug discovery and development company, Imago Pharmaceuticals. Under the terms of the agreement, Perrigo will receive an upfront payment in addition to multiple development-related milestone payments and royalties on any future sales derived...

2014-09-29 08:30:04

- AMAG Pharmaceuticals, Inc. to Acquire Lumara Health ST. LOUIS, Sept. 29, 2014 /PRNewswire/ -- Lumara Health(TM) today announced that it has entered into two separate definitive agreements for the sale of its Maternal Health business and separately, the sale of its Women's Healthcare assets. AMAG Pharmaceuticals, Inc. (Nasdaq: AMAG) will acquire Lumara Health, Inc. and its wholly owned subsidiaries, including its flagship product, Makena® (hydroxyprogesterone caproate...

2014-09-29 08:30:01

-- Expands Perrigo's Specialty Rx portfolio to include extended topical products in the women's healthcare category DUBLIN, Sept. 29, 2014 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO; TASE) announced today that it has signed a definitive agreement to acquire a portfolio of women's healthcare products from Lumara Health, Inc., a privately-held, Chesterfield, Missouri-based specialty pharmaceutical company, for $82 million in cash. The acquired portfolio generated more than $15...

2014-09-25 16:26:39

TORONTO, Sept. 25, 2014 /PRNewswire/ - Transition Therapeutics Inc. ("Transition" or the "Company") (TSX: TTH; NASDAQ: TTHI), a biopharmaceutical development company advancing novel therapeutics for CNS and metabolic disease indications, today announced its financial results for the year ended June 30, 2014. Selected Highlights Highlights for the Company during the year ended June 30, 2014 and up to the date of this MD&A include the following: ELND005: --...

2014-09-08 12:29:59

Commission Alleges That AbbVie Inc. and Besins Healthcare Inc. Filed Sham Lawsuits; AbbVie and Teva Pharmaceuticals USA, Inc. Entered Anticompetitive Agreement to Delay Generic Entry WASHINGTON, Sept. 8, 2014 /PRNewswire-USNewswire/ -- In its latest action to ensure competition in the nation's healthcare markets, the Federal Trade Commission has filed a complaint in federal district court charging several major pharmaceutical companies with illegally blocking American consumers' access to...

2014-09-02 16:26:04

DUBLIN, Sept. 2, 2014 /PRNewswire/ -- Perrigo Company plc, a public limited company incorporated under the laws of Ireland (the "Company"), today announced that it is offering to exchange (the "Exchange Offer") up to $500,000,000 of its new 1.30% Senior Notes due 2016 (the "2016 Exchange Notes"), $600,000,000 of its new 2.30% Senior Notes due 2018 (the "2018 Exchange Notes"), $800,000,000 of its new 4.00% Senior Notes due 2023 (the "2023 Exchange Notes") and $400,00,000 of its new...

2014-08-13 16:25:30

DUBLIN, Aug. 13, 2014 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO;TASE) today announced that its Board of Directors declared a quarterly dividend of $0.105 per share, payable on September 16, 2014 to shareholders of record on August 29, 2014. http://photos.prnewswire.com/prnvar/20120301/DE62255LOGO From its beginnings as a packager of generic home remedies in 1887, Perrigo Company plc, headquartered in Ireland, has grown to become a leading global healthcare supplier. Perrigo...

2014-07-31 08:36:33

DUBLIN, July 31, 2014 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO; TASE) today announced that it will release financial results for its fourth quarter and fiscal year 2014 on Thursday, August 14, 2014 at approximately 8:00 a.m. (ET). The Company will conduct a conference call at 10:00 a.m. (ET) hosted by Joseph C. Papa, Perrigo's Chairman, President and Chief Executive Officer. http://photos.prnewswire.com/prnvar/20120301/DE62255LOGO The conference call will be available live...

2014-07-30 08:33:18

DUBLIN, July 30, 2014 /PRNewswire/ -- Perrigo Company (NYSE: PRGO;TASE) announced that it has filed with the U.S. Food and Drug Administration (FDA) an Abbreviated New Drug Application for desoximetasone topical spray 0.25% and that it has notified Taro Pharmaceuticals U.S.A., Inc., the owner of the Reference Listed Drug of its filing. http://photos.prnewswire.com/prnvar/20120301/DE62255LOGO On July 28, 2014, Taro filed suit against Perrigo in the United States District Court for...

2014-07-24 12:28:04

DUBLIN, July 24, 2014 /PRNewswire/ -- Perrigo Company (NYSE: PRGO; TASE) today announced that it has received an AB therapeutic equivalent rating from the U.S. Food and Drug Administration (FDA) for its previously approved New Drug Application (NDA) for testosterone gel 1.0%. FDA concluded that Perrigo's testosterone product is therapeutically equivalent to [AbbVie's] AndroGel 1% and can be substituted with the full expectation that it will produce the same clinical effect and safety...


Word of the Day
caparison
  • A cloth or covering, more or less ornamented, laid over the saddle or furniture of a horse, especially of a sumpter-horse or horse of state.
  • Clothing, especially sumptuous clothing; equipment; outfit.
  • To cover with a caparison, as a horse.
  • To dress sumptuously; adorn with rich dress.
This word ultimately comes from the Medieval Latin 'cappa,' cloak.
Related